C-reactive protein and copeptin: Prognostic predictors in chronic obstructive pulmonary disease exacerbations

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 2, 2009, Pages 120-125

  Antonescu Turcu, Andreea L ^a,b   Tomic, Rade ^b  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Acute exacerbation of chronic obstructive pulmonary disease; C reactive protein; Copeptin; Systemic inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; CORTICOSTEROID; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; GLYCOPEPTIDES; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 62349134599     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283218603     Document Type: Review

References (37)

1. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
2. Danesh JM, Collins R, Appleby P, et al., Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 169:416-468.
3. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812.
4. Gan W, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and metaanalysis. Thorax 2004; 559:74-580.
5. Sin D, Man P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic pulmonary disease. Circulation 2003; 107:1514-1519.
6. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250-255. An 8-year cohort study that indicates that CRP level above 3 mg/l is a strong and independent predictor of hospitalization and deaths in patients with COPD.
7. de Torres JP, Cordoba-Lanus E, Lopez-Aguillar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27:902-907.
8. Broekhuizen R, Wouters EF, Creuztberg EC. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61:17-22.
9. Manino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114:758-762.
10. Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92:664-667.
11. Noguera A, Malo O, Sauleda J, et al. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease [in Spanish]. Arch Bronconeumol 2002; 38:172-176.
12. Spruit MA, Gosselink R, Troosters T, Kasran A. Muscle force during an acute exacerbation in hospitalized patients with COPD and its relationship with CXCL8 and IGF-1. Thorax 2003; 58:752-756.
13. Weis N, Almdal T. C-reactive protein: can it be used as a marker of infection in patient with exacerbation of chronic obstructive pulmonary disease? Eur J Int Med 2006; 17:88-91.
14. Bircan A, Gokirmak M, Kilic O, et al. C-reactive protein in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract 2008; 17:202-208. This retrospective analysis suggests that high CRP value may indicate an infectious exacerbation in COPD patients.
15. Wouter EF. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J 2006; 27:877-879.
16. Sin D, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760-765.
17. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive airway disease. Am J Respir Crit Care Med 2006; 173:71-78.
18. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117:1638-1645.
19. Stolz D, Christ-Grain M, Morgenthaler N, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131:1058-1067. Study suggests that copeptin may be a prognostic marker for short-term and long-term prognosis in patients admitted with COPD exacerbation.
20. Hurst J, Davidson G, Perera W, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-874.
21. Stolz D, Christ-Crain M, Gencay M, et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006; 136:434-440.
22. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and nonsmokers. Thorax 2006; 61:23-28.
23. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29:527-534. This prospective study suggests that high CRP level 14 days after an exacerbation of COPD may be predictor of recurrence within 50 days.
24. Cano NJ, Pichard C, Roth H, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126:540-546.
25. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weigh-ing the evidence. Curr Atheroscler Rep 2006; 8:421-428.
26. Linnemann B, Voigt W, Novel W, et al. C-reactive protein is a strong independent predictor of death in type II diabetes: association with multiple facets of metabolic syndrome. Exp Clin Endocrinol Diabetes 2006; 114:127-134.
27. Racki S, Zaputovic L, Mavric Z, et al. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006; 427-433.
28. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61:849-853.
29. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369.
30. Donaldson G. C-reactive protein: does it predict mortality? Am J Respir Crit Care Med 2007; 175:209-210.
31. de Torres JP, Pinot-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to severe COPD. Chest 2008; 133:1336-1343. Study assessed role of CRP as predictor of survival in patients with stable moderate-to-severe COPD.
32. Seligman R, Papassotiriou J, Morgenthaler NG, et al. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008; 12:R11. This prospective cohort study indicates that copeptin levels increase progressively with severity of sepsis and are independent predictors of mortality in patients with ventilator-associated pneumonia.
33. Muller B, Morgenthaler N, Stolz D, et al. Circulatory levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37:145-152. Copeptin may be a useful biomarker in the risk stratification of patients admitted with lower respiratory tract infection.
34. Westphal M, Siclenkamper AW, Van Aken H, et al. Dopexamine reverses the vasopressin-associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia. Anesth Analg 2004; 99:878-885.
35. Herrera EA, Riquelme RA, Sanhueza EM, et al. Cardiovascular responses to arginine vasopressin blockade during the acute hypoxemia in llama fetus. High Alt Med Biol 2000; 1:175-184.
36. Perez R, Espinoza M, Riquelme R, et al. Arginine vasopressin mediates cardiovascular responses to hypoxemia in fetal sheep. Am J Physiol 1989; 256:R1011-R1018.
37. Jin HK, Yang RH, Chen YF, et al. Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia. J Appl Physiol 1989; 66:151-160.